RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial

PURPOSE: Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world. The 3-year disease-free survival (DFS) in patients with locally-advanced disease is approximately 60% after primary radiochemotherapy (RCT). There is a strong rationale for combining immunotherapy w...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Daniel, Balermpas, Panagiotis, Gollrad, Johannes, Weiß, Christian, Valentini, Chiara, Stuschke, Martin, Schäfer, Henning, Henkenberens, Christoph, Debus, Jürgen, Krug, David, Kuhnt, Thomas, Brunner, Thomas, Bostel, Tilman, Engenhart-Cabillic, Rita, Nestle, Ursula, Combs, Stephanie E., Belka, Claus, Hautmann, Matthias, Hildebrandt, Guido, Gani, Cihan, Polat, Bülent, Rödel, Claus, Fokas, Emmanouil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218223/
https://www.ncbi.nlm.nih.gov/pubmed/32420463
http://dx.doi.org/10.1016/j.ctro.2020.04.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218223/
https://www.ncbi.nlm.nih.gov/pubmed/32420463
http://dx.doi.org/10.1016/j.ctro.2020.04.010

Ejemplares similares